NCT05266898View on ClinicalTrials.gov

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Papillomavirus VaccinesHuman Immunodeficiency VirusPapillomavirus InfectionSerologyCervical Intraepithelial NeoplasiaAnal Intraepithelial NeoplasiaOral Cavity Infection
Interventions
BIOLOGICAL

Human papillomavirus 9-valent vaccine, recombinant

Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)

BIOLOGICAL

human papillomavirus vaccine, recombinant

Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus. Administered as part of participant's clinical care prior to study enrollment (intervention not delivered as part of study design).

Trial Locations (1)

70112

RECRUITING

University Medical Center New Orleans, New Orleans

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Louisiana State University Health Sciences Center in New Orleans

OTHER